メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

滲出型AMD (加齢黄斑変性症) の世界市場:産業分析と将来展望 (2017〜2021年)

Global Wet Age Related Macular Degeneration (AMD) Market: Industry Analysis & Outlook 2017-2021

発行 Koncept Analytics 商品コード 493381
出版日 ページ情報 英文 74 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.20円で換算しております。
Back to Top
滲出型AMD (加齢黄斑変性症) の世界市場:産業分析と将来展望 (2017〜2021年) Global Wet Age Related Macular Degeneration (AMD) Market: Industry Analysis & Outlook 2017-2021
出版日: 2017年04月21日 ページ情報: 英文 74 Pages
概要

加齢黄斑変性症 (AMD) 患者のうち約90%が萎縮型 (ドライ) AMDに分類されますが、残りの約10%は滲出型 (ウェット) AMDに分類されます。これは、網膜内の脈絡膜に異常な新生血管が生じ、黄斑の機能障害を引き起こすという疾患です。滲出型AMDの治療は、抗VEGF (血管内皮細胞増殖因子) を用いて失明を防ぐという方法が一般的です。高齢者人口の増加や医療費支出の拡大を受けて、滲出型AMD治療薬の市場は更なる成長を遂げる、と期待されています。

当レポートでは、世界の滲出型AMD (加齢黄斑変性症) 治療薬の市場について分析し、疾患の概要や背景事情、世界全体の患者人口および治療済み患者数の見通し (今後5年間分)、滲出型AMD治療薬の市場規模、地域別・製品別の詳細動向、米国/それ以外の国々の市場動向 (市場規模、平均価格など)、主要企業のプロファイル・事業戦略といった情報を取りまとめてお届けいたします。

第1章 市場概要

  • イントロダクション
  • 加齢黄斑変性症 (AMD) の種類
  • AMDの治療オプション

第2章 世界市場の分析

  • 市場規模:患者人口
    • 滲出型AMD:患者人口 (予測値)
    • 滲出型AMD:患者人口のうち、VEG治療を受けた人数 (予測値)
    • 進行性・滲出型AMDの患者総人口/治療済み患者数
    • 進行性・滲出型AMDの患者総人口/治療済み患者数 (予測値)
  • 市場規模:金額ベース
    • 滲出型AMDの市場規模 (全世界、金額ベース)
    • 滲出型AMDの市場規模の予測値 (全世界、金額ベース)
  • 地域別の市場
  • 薬剤別の市場
    • 滲出型AMD向け医薬品の売上高の予測値 (全世界、金額ベース)

第3章 各地域市場の分析

  • 米国市場
    • 滲出型AMDの患者人口の予測値
    • 滲出型AMD患者:VEGF治療を受けた患者の予測値
    • 進行性・滲出型AMDの患者総人口/治療済み患者数
    • 進行性・滲出型AMDの患者総人口/治療済み患者数 (予測値)
    • 滲出型AMDの市場規模 (全世界、金額ベース)
    • 滲出型AMDの市場規模の予測値 (全世界、金額ベース)
    • 滲出型AMD市場:薬剤別
    • 滲出型AMD治療薬の売上高 (予測値)
  • 米国以外の市場

第4章 市場のダイナミクス

  • 成長促進要因
    • 高齢者人口の増加
    • 医療費の増大
    • 肥満人口の増加
    • 経済発展
  • 主な傾向
    • パイプライン上にある治験中のAMD治療薬リスト
    • 滲出型AMD治療薬の新たな技法
    • 滲出型AMD関連の治験認証件数の増加と認知度の上昇
  • 課題
    • 訓練を受けた眼科医の不足
    • 滲出型AMD治療薬の価格の高さ
    • 関連する高リスク要因

第5章 市場競争

  • 世界市場:滲出型AMD治療薬
    • 市場収益額:主要企業間の比較
    • 時価総額:主要企業間の比較
  • 米国市場:滲出型AMD治療薬
    • 平均価格 (服用量1回分当たり)、薬剤別
    • 普及率、薬剤別
  • 米国以外の市場:滲出型AMD治療薬
    • 平均価格 (服用量1回分当たり)、薬剤別
    • 普及率、薬剤別

第6章 企業プロファイル

  • Regeneron Pharmaceuticals, Inc.
    • 事業概要
    • 主な財務指標
    • 事業戦略
  • Novartis International AG
  • Roche Holding AG
  • Bayer Group

図表一覧

目次

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision that people need for "straight-ahead" activities such as reading, sewing, and driving. In some people, AMD advances so slowly that vision loss does not occur for a long time. In others, the disease progresses faster and may lead to a loss of vision in one or both eyes. As AMD progresses, a blurred area near the center of vision is a common symptom. Over time, the blurred area may grow larger or it may develop blank spots in central vision.

There are two types of AMD: Dry and Wet. About 90 per cent of AMD cases are classified as dry AMD. Usually, AMD starts as a dry type and can develop in one or both eyes. The process is slow and can advance over the course of several years. About 10 percent of all cases of Age-related Macular Degeneration become "Wet" AMD. It is a condition in which new blood vessels grow in the choroid layer behind the retina.

For wet AMD treatment, anti-vascular endothelial growth factor (anti-VEGF) is generally used which may halt or delay the progression of visual loss. By blocking the action of VEGF chemical, it helps prevent the condition from progressing and may partially reverse it. Anti-VEGF medicines include Eylea, Lucentis and Avastin. However, treatment in most people maintains vision and prevents the condition from becoming worse.

The global wet AMD market is set to experience favourable growth driven by factors such as increasing elderly population & rising health care expenditure. Further, the scope of growth for this market will be broadened by increasing obese population and global economic development. However, growth of this budding market will be hindered by lack of trained ophthalmologists, high cost of wet AMD drugs and associated high risk.

The report "Global Wet AMD market: Industry Analysis & Outlook (2017-2021)" analyses the development of this market, with focus on the U.S. and outside the U.S. markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Regeneron Pharmaceuticals, Inc. Novartis International AG, Roche Holding AG & Bayer Group are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global wet AMD market along with the study of the regional markets.

Table of Contents

1. Market Overview

  • 1.1 Introduction
  • 1.2 Types of AMD
  • 1.3 Treatment Options for AMD

2. Global Market Analysis

  • 2.1 Market by Patient Population
    • 2.1.1 Global Wet AMD Patient Population Forecast
    • 2.1.2 Global Wet AMD Patients on VEGF Therapy Forecast
    • 2.1.3 Global Advanced Wet AMD Population & Treated Patients
    • 2.1.4 Global Advanced Wet AMD Population & Treated Patients Forecast
  • 2.2 Market by Value
    • 2.2.1 Global Wet AMD Market by Value
    • 2.2.2 Global Wet AMD Market Forecast by Value
  • 2.3 Market by Region
  • 2.4 Market by Drug
    • 2.4.1 Global Wet AMD Drugs Sales Forecast by Value

3. Regional Market Analysis

  • 3.1 The U.S.
    • 3.1.1 The U.S. Wet AMD Patient Population Forecast
    • 3.1.2 The U.S. Wet AMD Patients on VEGF Therapy Forecast
    • 3.1.3 The U.S. Advanced Wet AMD Population & Treated Patients
    • 3.1.4 The U.S. Advanced Wet AMD Population & Treated Patients Forecast
    • 3.1.5 The U.S. Wet AMD Market by Value
    • 3.1.6 The U.S. Wet AMD Market Forecast by Value
    • 3.1.7 The U.S. Wet AMD Market by Drug
    • 3.1.8 The U.S. Wet AMD Drugs Sales Forecast by Value
  • 3.2 Outside The U.S.
    • 3.2.1 OUS Wet AMD Patient Population Forecast
    • 3.2.2 OUS Wet AMD Patients on VEGF Therapy Forecast
    • 3.2.3 OUS Advanced Wet AMD Population & Treated Patients
    • 3.2.4 OUS Advanced Wet AMD Population & Treated Patients Forecast
    • 3.2.5 OUS Wet AMD Market by Value
    • 3.2.6 OUS Wet AMD Market Forecast by Value
    • 3.2.7 OUS Wet AMD Market by Drug
    • 3.2.8 OUS Wet AMD Drug Sales Forecast by Value

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Rising Ageing Population
    • 4.1.2 Rising Healthcare Expenditure
    • 4.1.3 Increasing Obese Population
    • 4.1.4 Economic Development
  • 4.2 Key Trends
    • 4.2.1 Several Drugs Under Pipeline for AMD
    • 4.2.2 Novel Techniques for Wet AMD Drugs
    • 4.2.3 Increasing Research Grants and Awareness for Wet AMD
  • 4.3 Challenges
    • 4.3.1 Lack of Trained Ophthalmologists
    • 4.3.2 High Cost of Wet AMD Drugs
    • 4.3.3 Associated High Risk

5. Competition

  • 5.1 Global Market
    • 5.1.1 Global Wet AMD Market- Revenue Comparison of Key Companies
    • 5.1.2 Global Wet AMD Market- Market Cap Comparison of Key Companies
  • 5.2 The U.S.
    • 5.2.1 The U.S. Wet AMD Market- Price Per Dose by Drug
    • 5.2.2 The U.S. Wet AMD Market- Penetration Rate by Drug
  • 5.3 Outside the U.S.
    • 5.3.1 OUS Wet AMD Market- Price Per Dose by Drug
    • 5.3.2 OUS Wet AMD Market-Penetration Rate by Drug

6. Company Profiles

  • 6.1 Regeneron Pharmaceuticals, Inc.
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Novartis International AG
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Roche Holding AG
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Bayer Group
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies

List of Charts

  • Types of Age-Related Macular Degeneration (AMD)
  • Global Wet AMD Patient Population Forecast (2016-2021)
  • Global Wet AMD Patients on VEGF Therapy Forecast (2016-2021)
  • Global Advanced Wet AMD Population & Treated Patients (2012-2016)
  • Global Advanced Wet AMD Population & Treated Patients Forecast (2017-2021)
  • Global Wet AMD Market by Value (2012-2016)
  • Global Wet AMD Market Forecast by Value (2017-2021)
  • Global Wet AMD Market by Region (2016/2021)
  • Global Wet AMD Market Share by Drug (2016/2021)
  • Global Wet AMD Drugs Sales Forecast by Value (2016-2021)
  • The U.S. Wet AMD Patient Population Forecast (2016-2021)
  • The U.S. Wet AMD Patients on VEGF Therapy Forecast (2016-2021)
  • The U.S. Advanced Wet AMD Population & Treated Patients (2012-2016)
  • The U.S. Advanced Wet AMD Population & Treated Patient Forecast (2017-2021)
  • The U.S. Wet AMD Market by Value (2012-2016)
  • The U.S. Wet AMD Market Forecast by Value (2017-2021)
  • The U.S. Wet AMD Market by Drug (2016/2021)
  • The U.S. Wet AMD Drugs Sales Forecast by Value (2016-2021)
  • OUS Wet AMD Patient Population Forecast (2016-2021)
  • OUS Wet AMD Patients on VEGF Therapy Forecast (2016-2021)
  • OUS Advanced Wet AMD Population & Treated Patients (2012-2016)
  • OUS Advanced Wet AMD Population & Treated Patients Forecast (2017-2021)
  • OUS Wet AMD Market by Value (2012-2016)
  • OUS Wet AMD Market Forecast by Value (2017-2021)
  • OUS Wet AMD Market by Drug (2016/2021)
  • OUS Wet AMD Drugs Sales Forecast by Value (2016-2021)
  • Global Population Above 65 Years (2012-2016)
  • Global Healthcare Expenditure Per Capita (2012-2016)
  • Global Obese Population (2012-2016)
  • Global GDP Per Capita (2012-2016)
  • Global Wet AMD-Revenue Comparison of Key Companies (2016)
  • Global Wet AMD-Market Cap Comparison of Key Companies (2016)
  • The U.S. Wet AMD Market-Price Per Dose by Drug (2016-2021)
  • The U.S. Wet AMD Market-Penetration Rate by Drug (2016-2021)
  • OUS Wet AMD Market-Price Per Dose by Drug (2016-2021)
  • OUS Wet AMD Market-Penetration Rate by Drug (2016-2021)
  • Regeneron Pharmaceuticals, Inc. Revenue by Product (2016)
  • Regeneron Pharmaceuticals, Inc. Revenue and Net Income (2012-2016)
  • Novartis International AG Net Sales by Segments (2016)
  • Novartis International AG Net Sales and Net Income (2012-2016)
  • Roche Holding AG Sales by Segments (2016)
  • Roche Holding AG Net Sales and Net Income (2012-2016)
  • Bayer Group Sales by Segments (2016)
  • Bayer Group Net Sales and Net Income (2012-2016)
  • Products under Development for Wet AMD (2016)
Back to Top